{
    "2021-05-01": [
        [
            {
                "time": "2023-10-10",
                "original_text": "Novartis Phase III Beovu® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Beovu®",
                        "Phase III",
                        "fluid resolution",
                        "diabetic macular edema",
                        "fewer injections",
                        "aflibercept"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}